Abstract：Objective To analyze the effect of improved FOLFOX6 neoadjuvant chemotherapy and postoperative chemotherapy in progressive stomach cancer.Methods 46 progressive stomach cancer patients from November 2009 to December 2012 of our hospital were selected as study object for this study.46 progressive stomach cancer patients were random divided into control group and experimental group.23 progressive stomach cancer patients in control group were used improve FOLFOX6 postoperative chemotherapy and 23 progressive stomach cancer patients in experimental group were used improve FOLFOX6 neoadjuvant chemotherapy.The followed up of progressive stomach cancer patients in two groups were 3 years.The short term effect，three-year survival rate，time to tumor progression and the incidence rate of adverse effects of progressive stomach cancer patients in two groups were analyzed and compared.Results The incidence rate of adverse effects of progressive stomach cancer patients in control group was 47.83%，obvious higher than that was 21.74%in experimental group，and the short term effect，three-year survival rate，time to tumor progression of progressive stomach cancer patients between two groups had statistical significance （P＜0.05）.Conclusion Using improved FOLFOX6 neoadjuvant chemotherapy for progressive stomach cancer patients can enhance the survival time and quality of patients effectively，and with little adverse effects.
京公网安备 11010502046607号